CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes

Completed · Phase 1

Conditions studied: Rosacea

In brief

Open-label multicenter study using CGB-400 Gel to reduce facial redness, bumps, and blemishes.

Key facts

Study ID

NCT04508205

Run by

CAGE Bio Inc.

People needed

27

Starts

2018-10-26

Expected to finish

2019-04-18

Last updated by the study team

2020-08-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Outpatient, male or female of any race, 18 years of age or older. Female subjects of childbearing potential must have a negative UPT at Baseline and practice a reliable method of contraception throughout the study.
• Facial redness associated with rosacea with or without bumps or blemishes.
• Facial redness (IGA-R) score of 2 or 3 (i.e., mild or moderate).
• IGA score of 2 or 3 (i.e., mild or moderate).
• Absence of any skin conditions that could interfere with the visual erythema assessments.
• Willing to forego any other topical or non-topical treatment on the study areas during treatment (other than sun protection or the study specified face wash and moisturizer).
• Willing to use the provided skincare regimen (e.g., face wash and moisturizer) over the duration of the study.
• Sign the IRB-approved ICF (which includes HIPAA) prior to any study-related procedures being performed.

You may not qualify if…

• Known hypersensitivity or previous allergic reaction to any constituent of the Investigational Products (i.e., essential oils, fragrance, choline, phosphatidylcholine, etc.).
• Any transient flushing syndrome.
• History of basal cell carcinoma within 6 months of Visit 1.
• History or presence of a skin condition/disease that is located in the treatment area(s) and might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, psoriasis, significant actinic damage, vitiligo, open wounds, infection, etc.).
• Diagnosis of severe rosacea, ocular rosacea, rhinophymatous rosacea, or acne fulminans at Baseline.
• Blepharitis/meibomianitis requiring systemic treatment by an ophthalmologist.
• Uncontrolled systemic disease.
• Foreseen unprotected and intense/excessive UV exposure during the course of the study.
• Use of any of the following concomitant medications/procedures:
• Cosmetic and/or OTC products for redness reduction and/or skin clearing
• Topical medications for rosacea
• Systemic antibiotics or corticosteroids
• Topical antibiotics, corticosteroids, or antiparasitic agents
• Intense/excessive ultraviolet (UV) radiation
• Phototherapy, energy-based therapy, facials, chemical peels, microdermabrasion
• Exposure to any other investigational drug/device within 30 days prior to study entry.

Where it is running

• Cage Bio Investigative Site 1 — Fremont, California, United States
• Cage Bio Investigative Site 2 — San Diego, California, United States
• Cage Bio Investigative Site 3 — Edgewater, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.